Biodesix (BDSX) Current Deferred Revenue (2019 - 2026)

Biodesix (BDSX) has 8 years of Current Deferred Revenue data on file, last reported at $223000.0 in Q1 2026.

• Quarterly Current Deferred Revenue fell 71.7% year-over-year to $223000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $223000.0 (down 71.7% YoY) and the FY2025 annual result came in at $961000.0, up 37.29% from the prior year.
• Current Deferred Revenue retreated to $223000.0 in Q1 2026, from $961000.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $2.8 million in Q3 2025 to a low of $223000.0 in Q1 2026.
• A 5-year average of $1.1 million and a median of $788000.0 in 2025 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2024 — Current Deferred Revenue sank 72.73% — and 2025, when it jumped 300.0%.
• Tracing BDSX's Current Deferred Revenue over 5 years: stood at $962000.0 in 2022, then sank by 68.81% to $300000.0 in 2023, then soared by 133.33% to $700000.0 in 2024, then surged by 37.29% to $961000.0 in 2025, then slumped by 76.8% to $223000.0 in 2026.
• The last three Current Deferred Revenue figures came in at $223000.0 (Q1 2026), $961000.0 (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.